(Q36428042)

14 August 2017

1 reference

title

The therapeutic potential of monoamine oxidase inhibitors (English)

1 reference

14 August 2017

1

Moussa B H Youdim

1 reference

14 August 2017

Dale Edmondson

2

1 reference

PubMed ID

16552415

14 August 2017

Keith F Tipton

series ordinal

3

1 reference

PubMed ID

16552415

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Nature Reviews Neuroscience

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

295-309

1 reference

14 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrn1883

14 August 2017

0 references

cites work

Monoamine oxidase: from genes to behavior

1 reference

Monoamine oxidases: certainties and uncertainties

31 March 2020

1 reference

Monoamine oxidase expression during development and aging

31 March 2020

1 reference

Ontogenesis of multiple forms of monoamine oxidase in rat brain regions and liver.

31 March 2020

1 reference

Localization of monoamine oxidase (MAO) in the rat peripheral nervous system--existence of MAO-containing unmyelinated axons.

31 March 2020

1 reference

Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human.

31 March 2020

1 reference

The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions

31 March 2020

1 reference

Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET

31 March 2020

1 reference

Distinct monoamine oxidase A and B populations in primate brain.

31 March 2020

1 reference

A comparative study of the expression of monoamine oxidase-A and -B mRNA and protein in non-CNS human tissues.

31 March 2020

1 reference

Differential subcellular location of mitochondria in rat serotonergic neurons depends on the presence and the absence of monoamine oxidase type B

31 March 2020

1 reference

Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study

31 March 2020

1 reference

Different roles for type A and type B monoamine oxidase in regulating synaptic dopamine at D-1 and D-2 receptors associated with adenosine-3',5'-cyclic monophosphate (cyclic AMP) formation

31 March 2020

1 reference

Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity

31 March 2020

1 reference

Biogenic amines and the states of sleep

31 March 2020

1 reference

Calcineurin-mediated BAD Ser155 dephosphorylation in ammonia-induced apoptosis of cultured rat hippocampal neurons

31 March 2020

1 reference

Reactive oxygen species and the central nervous system

31 March 2020

1 reference

3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.

31 March 2020

1 reference

ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia

31 March 2020

1 reference

Potential roles of NF-kappaB and ERK1/2 in cytoprotection against oxidative cell death induced by tetrahydropapaveroline

31 March 2020

1 reference

Further studies on the endogenous inhibitor of monoamine oxidase in schizophrenic plasma

31 March 2020

1 reference

A comparison of platelet monoamine oxidase activity and phosphatidylserine content between chronic paranoid schizophrenics and normal controls

31 March 2020

1 reference

Bidirectional promoter of human monoamine oxidase A (MAO A) controlled by transcription factor Sp1.

31 March 2020

1 reference

Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1.

31 March 2020

1 reference

Monoamine oxidases A and B are differentially regulated by glucocorticoids and "aging" in human skin fibroblasts

31 March 2020

1 reference

Steroid regulation of monoamine oxidase activity in the adrenal medulla

31 March 2020

1 reference

Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes

31 March 2020

1 reference

Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A

31 March 2020

1 reference

Cloning, after cloning, knock-out mice, and physiological functions of MAO A and B

31 March 2020

1 reference

Dissociating barrel development and lesion-induced plasticity in the mouse somatosensory cortex.

31 March 2020

1 reference

Investigation of the functional effect of monoamine oxidase polymorphisms in human brain

31 March 2020

1 reference

Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression

31 March 2020

1 reference

Haplotypes of the monoamine oxidase genes and the risk for substance use disorders

31 March 2020

1 reference

Investigation of serotonin-related genes in antidepressant response

31 March 2020

1 reference

Low monoamine oxidase B in peripheral organs in smokers

31 March 2020

1 reference

Platelet monoamine oxidase, personality and alcoholism: the rise, fall and resurrection

31 March 2020

1 reference

Family-based case-control study of cigarette smoking and Parkinson disease

31 March 2020

1 reference

Transcription factor AP-2 and monoaminergic functions in the central nervous system

31 March 2020

1 reference

Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders

31 March 2020

1 reference

Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class

31 March 2020

1 reference

Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues

31 March 2020

1 reference

Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors

31 March 2020

1 reference

Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B

31 March 2020

1 reference

Positive selection in MAOA gene is human exclusive: determination of the putative amino acid change selected in the human lineage

31 March 2020

1 reference

Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A.

31 March 2020

1 reference

Structure and mechanism of monoamine oxidase

31 March 2020

1 reference

Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors

31 March 2020

1 reference

Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain

31 March 2020

1 reference

Monoamine oxidase type A: differences in selectivity towards l-norepinephrine compared to serotonin.

31 March 2020

1 reference

Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors.

31 March 2020

1 reference

Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B

31 March 2020

1 reference

Interactions of tricyclic antidepressant drugs with human and rat monoamine oxidase type B.

31 March 2020

1 reference

The discovery of antidepressants: a winding path

31 March 2020

1 reference

Interactions of monoamine oxidase with substrates and inhibitors

31 March 2020

1 reference

Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation

31 March 2020

1 reference

Monoamine oxidase inhibitors and the cheese effect

31 March 2020

1 reference

Selective monoamine oxidase inhibitors. 4. 4-Aminophenethylamine derivatives with neuron-selective action

31 March 2020

1 reference

Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase

31 March 2020

1 reference

Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

31 March 2020

1 reference

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

31 March 2020

1 reference

A clinical overview of monoamine oxidase inhibitors

31 March 2020

1 reference

Conventional and new antidepressant drugs in the elderly

31 March 2020

1 reference

Chronic treatment with the monoamine oxidase inhibitor phenelzine increases hypothalamic-pituitary-adrenocortical activity in male C57BL/6 mice: relevance to atypical depression

31 March 2020

1 reference

Corticotropin-releasing hormone in depression and post-traumatic stress disorder

31 March 2020

1 reference

Effects of selegiline (L-deprenyl) during smoking and short-term abstinence

31 March 2020

1 reference

Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation

31 March 2020

1 reference

A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers

31 March 2020

1 reference

Brain monoamine oxidase A inhibition in cigarette smokers

31 March 2020

1 reference

Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors

31 March 2020

1 reference

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

31 March 2020

1 reference

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

31 March 2020

1 reference

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

31 March 2020

1 reference

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

31 March 2020

1 reference

A novel formulation of selegiline for the treatment of Parkinson's disease

31 March 2020

1 reference

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

31 March 2020

1 reference

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

31 March 2020

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

31 March 2020

1 reference

Monoamine oxidase B inhibitors for early Parkinson's disease

31 March 2020

1 reference

A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?

31 March 2020

1 reference

Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine

31 March 2020

1 reference

Does phenylethylamine act as an endogenous amphetamine in some patients?

31 March 2020

1 reference

L-deprenyl induces aromatic L-amino acid decarboxylase (AADC) mRNA in the rat substantia nigra and ventral tegmentum. An in situ hybridization study.

31 March 2020

1 reference

Phenylethylaminergic modulation of catecholaminergic neurotransmission

31 March 2020

1 reference

What is it that l-deprenyl (selegiline) might do?

31 March 2020

1 reference

(-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition

31 March 2020

1 reference

(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.

31 March 2020

1 reference

Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity

31 March 2020

1 reference

Selegiline for Alzheimer's disease

31 March 2020

1 reference

L-deprenyl and physostigmine for the treatment of Alzheimer's disease.

31 March 2020

1 reference

Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

31 March 2020

1 reference

A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease

31 March 2020

1 reference

Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task.

31 March 2020

1 reference

Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats

31 March 2020

1 reference

Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis

31 March 2020

1 reference

Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

31 March 2020

1 reference

An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease

31 March 2020

1 reference

L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease

31 March 2020

1 reference

Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function

31 March 2020

1 reference

Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion

31 March 2020

1 reference

(-)-D-Deprenyl attenuates apoptosis in experimental brain ischaemia

31 March 2020

1 reference

Hydrogen peroxide production by monoamine oxidase during ischemia/reperfusion

31 March 2020

1 reference

Use of functional proteomics to investigate PKC epsilon-mediated cardioprotection: the signaling module hypothesis

31 March 2020

1 reference

Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members

31 March 2020

1 reference

Selegiline treatment facilitates recovery after stroke

31 March 2020

1 reference

Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type

31 March 2020

1 reference

Why (--)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects

31 March 2020

1 reference

Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats

31 March 2020

1 reference

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

31 March 2020

1 reference

Increased stress response and beta-phenylethylamine in MAOB-deficient mice

31 March 2020

1 reference

Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion

31 March 2020

1 reference

Aliphatic propargylamines, a new series of potent selective, irreversible non-amphetamine-like MAO-B inhibitors. Their structures, function and pharmacological implications.

31 March 2020

1 reference

Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases

31 March 2020

1 reference

Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine

31 March 2020

1 reference

Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration

31 March 2020

1 reference

Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases

31 March 2020

1 reference

3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease

31 March 2020

1 reference

Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition

31 March 2020

1 reference

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

31 March 2020

1 reference

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.

31 March 2020

1 reference

Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons

31 March 2020

1 reference

Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells

31 March 2020

1 reference

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

31 March 2020

1 reference

Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis

31 March 2020

1 reference

Mitochondria in cell death: novel targets for neuroprotection and cardioprotection

31 March 2020

1 reference

Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement

31 March 2020

1 reference

Parkinson's disease: mechanisms and models

31 March 2020

1 reference

Neurodegenerative diseases and oxidative stress

31 March 2020

1 reference

Neurodegenerative diseases and oxidative stress

31 March 2020

1 reference

Oxidative stress in neurodegeneration: cause or consequence?

31 March 2020

1 reference

Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes

31 March 2020

1 reference

Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells

31 March 2020

1 reference

(-) deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures

31 March 2020

1 reference

Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.

31 March 2020

1 reference

Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity

31 March 2020

1 reference

L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.

31 March 2020

1 reference

(-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide

31 March 2020

1 reference

Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl

31 March 2020

1 reference

L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia

31 March 2020

1 reference

(-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush

31 March 2020

1 reference

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

31 March 2020

1 reference

Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine

31 March 2020

1 reference

Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells

31 March 2020

1 reference

Clinical trials of neuroprotection for Parkinson's disease

31 March 2020

1 reference

Antioxidant effect of phenelzine on MPP+-induced cell viability loss in differentiated PC12 cells

31 March 2020

1 reference

Moclobemide reduces intracellular pH and neuronal activity of CA3 neurones in guinea-pig hippocampal slices-implication for its neuroprotective properties

31 March 2020

1 reference

Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity

31 March 2020

1 reference

Improvement of motor function in early Parkinson disease by safinamide

31 March 2020

1 reference

PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.

31 March 2020

1 reference

Apoptotic signaling cascades.

31 March 2020

1 reference

Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease

31 March 2020

1 reference

Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?

31 March 2020

1 reference

Neuroprotection in Parkinson's disease: clinical trials

31 March 2020

1 reference

Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl.

31 March 2020

1 reference

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

31 March 2020

1 reference

Dopamine induces proteasome inhibition in neural PC12 cell line.

31 March 2020

1 reference

Oxidative stress and mitochondrial-mediated apoptosis in dopaminergic cells exposed to methylcyclopentadienyl manganese tricarbonyl

31 March 2020

1 reference

Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl

31 March 2020

1 reference

Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain

31 March 2020

1 reference

Deprenyl, a therapeutic agent for Parkinson's disease, inhibits arsenic toxicity potentiated by GSH depletion via inhibition of JNK activation

31 March 2020

1 reference

MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo

31 March 2020

1 reference

Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

31 March 2020

1 reference

l-Deprenyl, blocking apoptosis and regulating gene expression in cultured retinal neurons

31 March 2020

1 reference

Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline

31 March 2020

1 reference

On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited

31 March 2020

1 reference

Is there a "non-MAO" macromolecular target for L-deprenyl?: Studies on MAOB mutant mice.

31 March 2020

1 reference

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

31 March 2020

1 reference

Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

31 March 2020

1 reference

Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.

31 March 2020

1 reference

Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

mRNA expression of neurotrophins and members of the trk family in the rat brain after treatment with L-deprenyl.

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRN1883

1 reference

14 August 2017

1 reference

PubMed ID

16552415